Presentation is loading. Please wait.

Presentation is loading. Please wait.

CHARM Program: 3 Component trials comparing candesartan with placebo.

Similar presentations


Presentation on theme: "CHARM Program: 3 Component trials comparing candesartan with placebo."— Presentation transcript:

1 CHARM Program: 3 Component trials comparing candesartan with placebo

2 CHARM Program: Baseline characteristics

3 CHARM Program: Baseline medications

4 CHARM-Overall: CV death and non-CV death

5 CHARM Program: Reduction in mortality and morbidity

6 CHARM Program: Reduction in CHF hospitalization

7 CHARM-Preserved: Hospital admissions for CHF

8 CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis

9 CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)

10 CHARM-Added: Effect of combined ACE inhibitor/  -blocker/AT1-receptor blocker

11 CHARM-Overall: Drug discontinuations for adverse events

12 CHARM: Clinical implications

13 CHARM-Overall: Reduction in new-onset diabetes

14 CHARM: Impact of treatment

15 HF with preserved LV systolic function in the elderly: Impact on survival

16 CHARM-Preserved: CV death or CHF hospitalization

17 CHARM-Preserved: Primary and secondary outcomes

18 CHARM-Preserved: Clinical implications

19 VALIANT: Design

20 VALIANT: Concomitant medications

21 VALIANT: Treatments show similar effect on outcome

22 VALIANT: Clinical implications

23 VALIANT: Effect of treatment on mortality—Subgroup analysis

24 RESOLVD: Comparative impact of ACE inhibitor, ARB, and  -blocker alone or combined on LVEF

25 Differences in dosing among ARB trials

26 Survival studies of  -blockade in HF

27  -Blockers improve survival in diabetic patients with HF: A meta-analysis

28 MERIT-HF:  -Blockade improves survival in CHF

29 MERIT-HF:  -Blockade improves survival in post-MI patients with HF

30 MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)

31 SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction

32 MERIT-HF: Effect of  -blockade on heart rate

33 MERIT-HF:  -Blockade decreases mortality and hospitalization independent of resting heart rate

34 CHRISTMAS: Design

35 CHRISTMAS: Trial profile

36 CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation

37 COMET: Trial profile

38 COMET: All-cause mortality

39 COMET: Heart rate at each visit

40 COMET: Blood pressure

41  -Blocker HF trials: Mortality results

42 Mortality rates in perspective CIBIS-II, MERIT-HF, COMET

43 Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences

44 COMET: Clinical implications

45 Comparison of  -blocker effects in major HF trials

46 Not all  -blockers are the same


Download ppt "CHARM Program: 3 Component trials comparing candesartan with placebo."

Similar presentations


Ads by Google